Company Encyclopedia
View More
name
AMOYTOP
688278.SH
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd.
1.556 T
688278.SHMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
A
BiotechnologyIndustry
Industry Ranking1/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE35.63%A
    • Profit Margin28.11%A
    • Gross Margin91.98%A
  • Growth ScoreA
    • Revenue YoY28.77%A
    • Net Profit YoY26.85%B
    • Total Assets YoY41.10%A
    • Net Assets YoY32.89%A
  • Cash ScoreB
    • Cash Flow Margin355.69%C
    • OCF YoY28.77%A
  • Operating ScoreA
    • Turnover1.03A
  • Debt ScoreA
    • Gearing Ratio20.52%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Asian Market Stocks Estimated Up To 26% Below Intrinsic Value

    Asian stocks are estimated to be up to 26% below intrinsic value, presenting growth opportunities for investors. Key undervalued stocks include Xi'an NovaStar Tech, Xiamen Amoytop Biotech, and Ningbo Sanxing Medical Electric, among others. Despite volatility, these stocks show potential for significant earnings growth. The article highlights the importance of identifying undervalued stocks in a complex market environment, offering insights into their financial health and growth forecasts.

    Simplywall·
    SH
    601567
    +0.70%
    SZ
    301589
    +6.94%
    SH
    688278
    +0.44%
    Simplywall·
    SH
    601567
    +0.70%
    SZ
    301589
    +6.94%
    SH
    688278
    +0.44%

    Amoytop Biotech's Q3 Profit Slips 5%, Revenue Jumps 27%; Shares Down 6%

    Amoytop Biotech's Q3 Profit Slips 5%, Revenue Jumps 27%; Shares Down 6%

    marketscreener·
    SH
    688278
    +0.44%
    marketscreener·
    SH
    688278
    +0.44%

    Beijing eGOVA Co,. Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025

    Beijing eGOVA Co., Ltd reported earnings for the nine months ended September 30, 2025, with sales of CNY 520.73 million, down from CNY 697.67 million the previous year. The company experienced a net loss of CNY 52.2 million, compared to a net income of CNY 20.5 million a year ago. Basic and diluted loss per share from continuing operations were both CNY 0.084, contrasting with earnings per share of CNY 0.0332 in the prior year.

    marketscreener·
    SZ
    300075
    +1.54%
    marketscreener·
    SZ
    300075
    +1.54%

    AMOYTOP released its performance for the first three quarters, with a net profit attributable to the parent company of 666 million yuan, a year-on-year increase of 20.21%

    According to the Zhitong Finance APP, AMOYTOP disclosed its third-quarter report for 2025. The company achieved revenue of 2.48 billion yuan in the first three quarters, a year-on-year increase of 26.85%; the net profit attributable to shareholders of the listed company was 666 million yuan, a year-on-year increase of 20.21%; the net profit excluding non-recurring gains and losses was 673 million yuan, a year-on-year increase of 15.91%; the basic earnings per share were 1.64 yuan

    Zhitong·
    SH
    688278
    +0.44%
    Zhitong·
    SH
    688278
    +0.44%

    Xiamen Amoytop Biotech Q3 net profit down 4.6% Y/Y

    Xiamen Amoytop Biotech Q3 net profit down 4.6% Y/Y

    marketscreener·
    SH
    688278
    +0.44%
    marketscreener·
    SH
    688278
    +0.44%
    © 2025 Longbridge｜Disclaimer